KR20220004142A - Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법 - Google Patents

Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법 Download PDF

Info

Publication number
KR20220004142A
KR20220004142A KR1020217038842A KR20217038842A KR20220004142A KR 20220004142 A KR20220004142 A KR 20220004142A KR 1020217038842 A KR1020217038842 A KR 1020217038842A KR 20217038842 A KR20217038842 A KR 20217038842A KR 20220004142 A KR20220004142 A KR 20220004142A
Authority
KR
South Korea
Prior art keywords
structural formula
compound represented
formula
iii
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217038842A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 클링턴 오스타드
데이비드 쥐. 로
Original Assignee
카리오팜 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카리오팜 쎄라퓨틱스, 인코포레이티드 filed Critical 카리오팜 쎄라퓨틱스, 인코포레이티드
Publication of KR20220004142A publication Critical patent/KR20220004142A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217038842A 2019-05-01 2020-05-01 Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법 Pending KR20220004142A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841649P 2019-05-01 2019-05-01
US62/841,649 2019-05-01
PCT/US2020/031124 WO2020223678A1 (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Publications (1)

Publication Number Publication Date
KR20220004142A true KR20220004142A (ko) 2022-01-11

Family

ID=70802955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038842A Pending KR20220004142A (ko) 2019-05-01 2020-05-01 Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법

Country Status (14)

Country Link
US (1) US12479806B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962898A1 (cg-RX-API-DMAC7.html)
JP (2) JP7630444B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004142A (cg-RX-API-DMAC7.html)
CN (1) CN114040909B (cg-RX-API-DMAC7.html)
AU (1) AU2020266170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021706A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135712A1 (cg-RX-API-DMAC7.html)
CR (1) CR20210590A (cg-RX-API-DMAC7.html)
IL (1) IL287673B1 (cg-RX-API-DMAC7.html)
MA (1) MA55808A (cg-RX-API-DMAC7.html)
MX (1) MX2021013211A (cg-RX-API-DMAC7.html)
SG (1) SG11202111993SA (cg-RX-API-DMAC7.html)
WO (1) WO2020223678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法
JP2021048976A (ja) * 2019-09-24 2021-04-01 株式会社ユニバーサルエンターテインメント 遊技機
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法

Also Published As

Publication number Publication date
AU2020266170A1 (en) 2021-11-25
US20220242832A1 (en) 2022-08-04
CR20210590A (es) 2022-03-11
JP2025072490A (ja) 2025-05-09
JP2022531576A (ja) 2022-07-07
JP7850834B2 (ja) 2026-04-23
CA3135712A1 (en) 2020-11-05
WO2020223678A1 (en) 2020-11-05
US12479806B2 (en) 2025-11-25
MX2021013211A (es) 2022-03-11
SG11202111993SA (en) 2021-11-29
IL287673B1 (en) 2026-01-01
EP3962898A1 (en) 2022-03-09
MA55808A (fr) 2022-03-09
JP7630444B2 (ja) 2025-02-17
CN114040909A (zh) 2022-02-11
IL287673A (en) 2021-12-01
BR112021021706A2 (pt) 2022-04-19
AU2020266170B2 (en) 2026-02-26
CN114040909B (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
JP7850834B2 (ja) Ｘｐｏ１阻害剤の調製プロセス及びｘｐｏ１阻害剤の調製に用いられる中間体
AU2022204648B2 (en) Synthesis of omecamtiv mecarbil
TWI735759B (zh) 細胞凋亡誘導劑之中間體及其製備方法
CN112047888B (zh) 一种合成恩杂鲁胺的方法
JP2025523949A (ja) ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンズイミダゾール－６－カルボン酸、１，３－ジヒドロキシ－２－（ヒドロキシメチル）プロパン－２－アミン塩を調製するための方法および中間体
WO2004083212A1 (en) Process to beta-ketoamide intermediates to dipeptidyl peptidase inhibitors
WO2008150481A2 (en) Processes for the preparation of crystalline form beta of imatinib mesylate
JP7777527B2 (ja) （９Ｓ）－２－ブロモ－９－（２，３，４－トリフルオロフェニル）－６，７，８，９－テトラヒドロ－５Ｈ－［１，２，４］トリアゾロ［１，５－ａ］アゼピンの製造方法
CA2915841C (en) Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
JP5078211B2 (ja) 複素環式化合物の製造方法
JP2022543057A (ja) 結晶形ｉｉのソタグリフロジンを調製する方法
JP2013508418A (ja) １−（４−（（１ｒ，２ｓ，３ｒ）−１，２，３，４−テトラヒドロキシブチル）−１ｈ−イミダゾール−２−イル）エタノンを調製する方法
JP7492997B2 (ja) オラパリブの製造方法
JP5441913B2 (ja) カルボニルオキシ化合物の製造方法
WO2024110862A9 (en) Process for preparing zanubrutinib
KR20250130961A (ko) 신규한 유파다시티닙 결정형 i의 제조방법 및 신규한 유파다시티닙 결정형 i
HK40068051B (en) Synthesis of omecamtiv mecarbil
KR20220064248A (ko) Trk 억제제 화합물의 제조 방법
JPH09216886A (ja) トリアゾロピリダジン誘導体の製造法
HK40025477A (en) Synthesis of omecamtiv mecarbil
HK40025477B (en) Synthesis of omecamtiv mecarbil

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701